Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$11,623 | -$17,192 | -$24,277 | -$24,457 |
| Dep. & Amort. | $240 | $265 | $285 | $260 |
| Deferred Tax | $0 | $0 | $1,339 | $0 |
| Stock-Based Comp. | $750 | $1,490 | $1,682 | $1,366 |
| Change in WC | $1,687 | -$496 | $2,990 | -$3,434 |
| Other Non-Cash | -$147 | -$4,525 | -$1,339 | $0 |
| Operating Cash Flow | -$9,093 | -$20,458 | -$19,320 | -$26,265 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$18 | -$29 | -$330 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $1,027 | $0 |
| Other Inv. Act. | $12 | $2,211 | $0 | $653 |
| Investing Cash Flow | $12 | $2,193 | $998 | $323 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $7,967 | $18,978 | $238 | $6,964 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $5 |
| Financing Cash Flow | $7,967 | $18,978 | $238 | $6,969 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$1,114 | $713 | -$18,084 | -$18,973 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $1,485 | $772 | $18,856 | $37,829 |
| End Cash | $371 | $1,485 | $772 | $18,856 |
| Free Cash Flow | -$9,093 | -$20,476 | -$19,349 | -$26,595 |